Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TAC-101 by Triumvira Immunologics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
TAC-101 is under clinical development by Triumvira Immunologics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
TAC-101 by Triumvira Immunologics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
TAC-101 is under clinical development by Triumvira Immunologics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...
TAC-101 by Triumvira Immunologics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
TAC-101 is under clinical development by Triumvira Immunologics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...
TAC-101 by Triumvira Immunologics for Non-Small Cell Lung Cancer: Likelihood of Approval
TAC-101 is under clinical development by Triumvira Immunologics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
TAC-101 by Triumvira Immunologics for Solid Tumor: Likelihood of Approval
TAC-101 is under clinical development by Triumvira Immunologics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
TAC-101 by Triumvira Immunologics for Gastric Cancer: Likelihood of Approval
TAC-101 is under clinical development by Triumvira Immunologics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
TAC-101 by Triumvira Immunologics for Colorectal Cancer: Likelihood of Approval
TAC-101 is under clinical development by Triumvira Immunologics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
TAC-101 by Triumvira Immunologics for Ovarian Cancer: Likelihood of Approval
TAC-101 is under clinical development by Triumvira Immunologics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
TAC-101 by Triumvira Immunologics for Gallbladder Cancer: Likelihood of Approval
TAC-101 is under clinical development by Triumvira Immunologics and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase...